Amgen plans to buy ChemoCentryx, a one-drug Bay Area biotech, for $3.7 billion


The deal could be a sign of a pick-up in mergers and acquisitions in the Bay Area's biotechnology space.

Previous Bank of America promotes Philly exec with oversight of Pittsburgh market president to bigger role
Next Most Influential Business Women 2022: Carlita Vasser uses years of nursing experience to lead At Home Care